Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci Corp's financial outlook is bolstered by the increasing rNPV to $1.6 billion, reflecting a positive adjustment to forecasts following the inclusion of their ABS-201 product. The anticipated positive interim efficacy readout from the MAD study in AGA patients, expected in the latter half of 2026, is viewed as a significant catalyst that could enhance investor interest. Additionally, strong preclinical evidence supporting ABS-201's unique mechanism of action, coupled with high demand for in-office treatments among prospective patients, contributes to a favorable sentiment surrounding the company's growth potential.

Bears say

Absci Corp faces several significant risks that could hinder its performance, including technology, clinical, regulatory, and commercial challenges that may impact future partnerships and market entry. The company's focus on treating conditions with high treatment burdens, such as androgenetic alopecia (AGA), highlights a gap in standard of care (SOC) for non-hormonal options, potentially limiting patient adoption of its offerings. Additionally, market dynamics, including competition and the potential for intellectual property issues, coupled with the risk of dilution, contribute to an overall negative outlook for Absci's stock.

Absci Corp (ABSI) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.98, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.98, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.